XML 86 R62.htm IDEA: XBRL DOCUMENT v3.24.2.u1
License, Acquisitions and Other Agreements - Acquisitions (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended
May 03, 2024
May 01, 2024
Jan. 07, 2024
May 31, 2024
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2024
Dec. 31, 2023
License and other agreements                
Success-based milestone payments, based on regulatory approval         $ 185,000   $ 185,000  
Additional regulatory milestone payments         60,000   60,000  
Forward contract and derivative liabilities         81,220   81,220 $ 0
Purchase Agreement, Knopp Amendment                
License and other agreements                
Common stock issued (shares)       1,872,874        
Issuance of common shares, net of offering costs       $ 65,981        
Purchase Agreement, Knopp Amendment                
License and other agreements                
Number of securities called by warrants (shares)   294,195            
Exercise price of warrants (in dollars per share)   $ 67.98            
Purchase Agreement, Knopp Amendment                
License and other agreements                
Issuance of common shares, net of offering costs   $ 75,000            
Gain on derivative       $ 9,239        
Purchase Agreement, Knopp Amendment, 2025 Additional Consideration                
License and other agreements                
Common shares issuable, value $ 75,000              
Forward contract, current and written put option, current                
License and other agreements                
Forward contract and derivative liabilities 75,220              
Derivative Liability, 2024 Additional Consideration | Level 3                
License and other agreements                
Fair value 15,540              
2024 Additional Consideration True-up | Level 3                
License and other agreements                
Change in fair value of derivative in other income (expense), net         (590)      
Forward Contract Liability, 2025 Addtional Consideration                
License and other agreements                
Issuance of common shares, net of offering costs             75,000  
Forward Contract Liability, 2025 Addtional Consideration | Level 3                
License and other agreements                
Fair value   $ 63,940            
Change in fair value of derivative in other income (expense), net         (1,150)      
2025 Additional Consideration True-up | Level 3                
License and other agreements                
Fair value $ 13,810              
Change in fair value of derivative in other income (expense), net         1,630      
Pyramid Biosciences, Inc.                
License and other agreements                
Upfront payment of common shares, shares (in shares)     255,794,000          
Upfront payment of common shares, value     $ 10,894          
Research and development           $ 5,689    
Common shares issuable (in shares)           98,129    
Pyramid Biosciences, Inc. | Developmental And Regulatory Milestones, First Asset | Lead Asset                
License and other agreements                
Success-based payments         5,000   5,000  
Pyramid Biosciences, Inc. | Developmental And Regulatory Milestones, Second Asset | Second Asset                
License and other agreements                
Success-based payments         30,000   30,000  
Pyramid Biosciences, Inc. | Commercial Sales-Based Milestones                
License and other agreements                
Success-based payments         $ 40,000   $ 40,000